PatientsVille.com Logo

PRODUCT QUALITY ISSUE and Prednisone

PatientsVille

PRODUCT QUALITY ISSUE Symptoms and Causes

We all need clean water. People need it to grow crops and to operate factories, and for drinking and recreation. Fish and wildlife depend on it to survive.

Many different pollutants can harm our rivers, streams, lakes, and oceans. The three most common are soil, nutrients, and bacteria. Rain washes soil into streams and rivers. The soil can kill tiny animals and fish eggs. It can clog the gills of fish and block light, causing plants to die. Nutrients, often from fertilizers, cause problems in lakes, ponds, and reservoirs. Nitrogen and phosphorus make algae grow and can turn water green. Bacteria, often from sewage spills, can pollute fresh or salt water.

You can help protect your water supply:

  • Don't pour household products such as cleansers, beauty products, medicines, auto fluids, paint, and lawn care products down the drain. Take them to a hazardous waste collection site.
  • Throw away excess household grease (meat fats, lard, cooking oil, shortening, butter, margarine, etc.) diapers, condoms, and personal hygiene products in the garbage can.
  • Clean up after your pets. Pet waste contains nutrients and germs.

Environmental Protection Agency

Check out the latest treatments for PRODUCT QUALITY ISSUE

PRODUCT QUALITY ISSUE treatment research studies

Prednisone clinical trials, surveys and public health registries


Find Drug Side Effect reports



Prednisone Side Effects

Dyspnoea (309)
Pyrexia (283)
Nausea (273)
Pain (263)
Diarrhoea (255)
Arthralgia (247)
Fatigue (246)
Headache (234)
Pneumonia (231)
Pain In Extremity (210)
Asthenia (210)
Vomiting (205)
Dizziness (201)
Oedema Peripheral (198)
Weight Increased (187)
Weight Decreased (175)
Abdominal Pain (172)
Back Pain (169)
Condition Aggravated (161)
Anaemia (156)
Crohn's Disease (113)
Sepsis (110)
Osteonecrosis (105)
Dehydration (104)
Malaise (104)
Fall (101)
Insomnia (100)
Death (100)
Injection Site Pain (100)
Chest Pain (97)
Cough (96)
Confusional State (96)
Diabetes Mellitus (91)
Rash (89)
Blood Glucose Increased (88)
Anxiety (88)
Pulmonary Embolism (88)
Rheumatoid Arthritis (85)
Pruritus (83)
Hypertension (82)
Hypotension (80)
Depression (80)
Febrile Neutropenia (79)
Erythema (78)
Renal Failure (77)
Neutropenia (74)
Deep Vein Thrombosis (73)
Renal Failure Acute (71)
Hyperglycaemia (69)
Muscular Weakness (69)

➢ More


Common Meds

Abilify (10132)
Adderall (1304)
Amlodipine (6664)
Amoxicillin (4387)
Benadryl (1568)
Celebrex (12876 )
Celexa (1342)
Cialis (2975)
Cipro (8580)
Citalopram (7792)
Crestor (18839)
Cymbalta (14373)
Doxycycline (1757)
Effexor (7289)
Flexeril (435)
Flomax (2177)
Fluoxetine (4261)
Gabapentin (4593)
Hydrocodone (2469)
Ibuprofen (8222)
Lantus (10968)
Lexapro (3499)
Lipitor (17769)
Lisinopril (8919)
Lyrica (27148)
Medrol (650)
Mirena (41254)
Mobic (957)
Morphine (5356)
Naproxen (538)
Neurontin (6501)
Oxycodone (4438)
Pradaxa (13372)
Prednisone (5926)
Prilosec (2631)
Prozac (1954)
Seroquel (27216)
Simvastatin (8348)
Synthroid (4452)
Tamiflu (5585)
Topamax (3748)
Tramadol (5054)
Trazodone (1458)
Viagra (5394)
Vicodin (1153)
Wellbutrin (6324)
Xanax (2847)
Zocor (5718)
Zoloft(6792)
Zyrtec(1669)

Recent Reviews

>:o :'(

3 weeks after i had been given 120m of predisone in a 24 hour period,i started getting dizzy spells severe enough that initially i blacked out while driving,needless to say i havent been driving my car,but i still am experiencing very bad dizzy spell

66 year old male. Good to excellent health. Non smoker, non drinker. Slowly deteriorated till all joints were swollen and eventually I became 99% immobile. Diagnosis? Spotless, Rocky Mountain Spotted Fever. (erlickiosis chaffnesis) Hospitalized, inf

Female patient 39 taking prednisone for asthma. Prednisone 20 mg 4 days on and then one day off/one day onfor8 days. Menstrual type bleeding although not during menstrual period. Severe pelvic cramps and urgency of urination. Swol

I am asthmatic (since I was very little) 36yrs old, took 40mg Prednisone for 8 days - two days later I ovulated and then I started bleeding uncontrollably. Gynae said ovaries failed as blood work tested very low and put me on Duphaston to aid drying

I have taken Prednisone for severe asthma on many occassions (including IV in hospital for 7 days) and suffered severe abdominal pain. Three years ago a gastroscopy revealed I had Duodenal ulcers and Gastritis, most likely caused from the Prednisilo

I take it when i get poison oak or ivy really bad and it takes it away in like 3 days if im fully broken out and i am highly allergic poison ivy, oak and all of that other stuff like that and this stuff helps me tremendously :-D

I take prednione 10mg : 3 tablets once daily for 3 days,then 2 tablets once daily for 3 days,then 1 tabletonce daily for 3 days, then hallf tablets for 4 days. Prednisone give more energy because I have Refractory Anemia with Ringed oblast

I was on a higher dosage - 40mg for 8 days and a few days after I stopped, I started with a 'breakthrough' bleed. Had to have blood tests taken and it showed ovarian failure which DR said could be strongly linked to Prednisone... I am not convinced i

I was recently diagnosed as having rheumatoid arthritis one of the meds prescribed was prednisone one of the side affects that i have noticed is my stomach cramps inthe evening. gonna check to see if I can get a different prescrition

Dear Sir/Madam, We are 'Alispo International' from Sialkot Pakistan. As a manufacturer, we supply 'SURGICAL DENTAL HAND INSTRUMENTS' in high quality, including Gynecology, ENT, Ophthalmic, Cardiac, Orthodontic and endodontic instruments. O

i never had an issue with using theraflu before. this time around i feel drunk every time i take it. i feel really super drowsy. and it is not working at all. i am still very congested even though i have a runny nose. i am still sore all over even t

>:o Took my first dose today,it left me covered in a red itchy rash on neck,chest,back and sides within 10 minutes of consuming.This product is now sitting in the trash can. :(

Hey Michelle, we almost have the same issue..I switched from Yaz to Trinessa because I and my husband thought it caused my severe mood swings prior to my period. I have been running and working out but I start experiencing joint

<span style='color: #808080;'><b>Describe Your Nystagmus from DTAP + IPV + HIB (PENTACEL) 2010 Experience Here: My duagters very first set of vaccination shots at 3 months caused nystagmus. We did not notice the issue

'OCAS' means that the product is administered over a time period. For this reason it must be swallowed whole and not chewed.

....however, dalacine is very effective unto face. kaya ngaun patuloy na ang paggamit ko sa product na ito.. try niyo rin para masubukan niyo. sabi nga hindi mo malalaman ang tamis hangat hindi mo nasusubukan ang pa.it....jejejeje' &nb

1.2-methyl-2-butene is treated with the following reagents write the structural formula of the mian organic product in each case

According to unspsc classification ,in which commodity this product fall?

After i use sensordyne , i have extremely pain travel from the back of my throat and uperjaw to my head . I though this product will reduce sensitivity in my teeth , now i have more pain then before.

PRODUCT QUALITY ISSUE Clinical Trials and Studies

Treatments might be new drugs or new combinations of drugs, new surgical procedures or devices, or new ways to use existing treatments. The goal of clinical trials is to determine if a new test or treatment works and is safe. Clinical trials can also look at other aspects of care, such as improving the quality of life for people with chronic illnesses. People participate in clinical trials for a variety of reasons. Healthy volunteers say they participate to help others and to contribute to moving science forward. Participants with an illness or disease also participate to help others, but also to possibly receive the newest treatment and to have the additional care and attention from the clinical trial staff.
Rank Status Study
1 Recruiting Subcutaneous Velcade Plus Oral Melphalan and Prednisone or Plus Cycloposphamide and Prednisone or Plus Prednisone
Condition: Multiple Myeloma
Interventions: Drug: velcade subcutaneous melphalan Prednisone;   Drug: velcade cyclophosphamide Prednisone;   Drug: velcade Prednisone
Outcome Measures: Very Good Partial Response, Complete response rate , Partial response rate;   Progression free survival;   Time to progression;   Time to Next Therapy;   Overall survival;   Time to response;   Duration of response;   Response rate
2 Recruiting The Assessment of Prednisone In Remission Trial (TAPIR) - Patient Centric Approach
Conditions: Granulomatosis With Polyangiitis;   Wegener Granulomatosis;   Vasculitis
Interventions: Drug: 5 mg Prednisone;   Drug: 0 mg Prednisone
Outcome Measures: Prednisone dose increase for disease relapse;   Rates of disease flare sub types;   Time to event flare;   Health related quality of life;   Safety Outcomes;   Protocol performance
3 Recruiting The Assessment of Prednisone In Remission Trial - Centers of Excellence Approach
Condition: Granulomatosis With Polyangiitis
Interventions: Drug: Prednisone 5 mg/day;   Drug: Prednisone 0 mg/day
Outcome Measures: Physician decision to increase glucocorticoids for disease relapse.;   Time to disease flare.;   Safety outcomes.;   Protocol performance at VCRC Centers of Excellence.;   Health-related quality of life survey;   Health-related quality of life surveys
4 Recruiting Use of a Single Dose of Oral Prednisone in the Treatment of Cellulitis
Condition: Cellulitis
Interventions: Drug: Prednisone;   Drug: Placebo
Outcome Measures: Change in VAS for pain - day 1 to 48 hours;   Change in erythema size - day 1 to 48 hours;   Amount of pain medication - day 1 to 48 hours;   Amount of pain medication - day 1 to 7 days;   Amount of pain medication - 48 hours to 7 days;   Additional Medical Assistance Post-Randomization;   Disposition Trend;   Adverse Events
5 Recruiting Phase 3 Study of Carfilzomib, Melphalan, Prednisone vs Bortezomib, Melphalan, Prednisone in Newly Diagnosed Multiple Myeloma (CLARION)
Condition: Multiple Myeloma
Interventions: Drug: Carfilzomib;   Drug: Bortezomib;   Drug: Melphalan;   Drug: Prednisone
Outcome Measures: Progression-Free Survival;   Overall Survival (OS);   Complete Response (CR) rate;   Overall Response Rate (ORR);   Change from baseline in health-related quality of life (HR-QOL) score
6 Recruiting Treatment of Prednisone Plus Cyclophosphamide in Patients With Advanced-stage IgA Nephropathy
Condition: IgA Nephropathy
Interventions: Drug: Prednisone plus cyclophosphamide;   Drug: Prednisone alone
Outcome Measures: the changes of kidney function;   the changes of proteinuria
7 Recruiting Efficacy of Prednisone in Patients With Severe Systemic Atheroembolism (Cholesterol Cristal Embolism)
Condition: Cholesterol Embolism Systemic
Interventions: Drug: Prednisone;   Other: placebo
Outcome Measures: 1-year survival and 1-year renal survival (composite criteria);   Number and duration of hospitalization(s);   course of renal function;   number of cardiovascular events;   Prednisone tolerance
8 Recruiting Reolysin Combined With Docetaxel and Prednisone or Docetaxel and Prednisone Alone in Metastatic Castration Resistant Prostate Cancer
Condition: Prostate Cancer
Interventions: Drug: Docetaxel, Reolysin and Prednisone;   Drug: Docetaxel and Prednisone
Outcome Measures: Disease Progression;   Effect of Docetaxel and Reolysin on circulating tumour cells;   PSA change rate;   Objective Response;   Overall Survival;   Determine patient tolerability and toxicity of Reolysin and Docetaxel in combination;   Prognostic/Predictive molecular response
9 Not yet recruiting Study of the Prednisone Sparing Effect of Xolair (Omalizumab) in Patients With Prednisone-dependent Asthma With Eosinophilic Bronchitis
Conditions: Prednisone Dependent Asthma;   Eosinophilic Bronchitis
Interventions: Biological: Omalizumab (Xolair);   Drug: Placebo
Outcome Measures: proportion of patients with exacerbations in each study group from week 0 to week 32.;   the magnitude of the reduction in the dose of Prednisone from week 12 to week 32.;   change in % sputum eosinophil;   Blood eosinophils;   Forced Expired Volume in 1 second (FEV1);   Ratio of Forced Expired Volume in 1 second to Forced Vital Capacity (FEV1/VC);   Provocative concentration causing a 20% drop in FEV1 (PC20);   Asthma Control Questionnaire;   Fraction of exhaled nitric oxide (FeNO)
10 Not yet recruiting Blinatumomab and Combination Chemotherapy or Dasatinib, Prednisone, and Blinatumomab in Treating Older Patients With Newly Diagnosed Acute Lymphoblastic Leukemia
Conditions: Philadelphia Chromosome Negative Adult Precursor Acute Lymphoblastic Leukemia;   Philadelphia Chromosome Positive Adult Precursor Acute Lymphoblastic Leukemia;   Untreated Adult Acute Lymphoblastic Leukemia
Interventions: Biological: blinatumomab;   Drug: Prednisone;   Drug: vincristine sulfate;   Drug: methotrexate;   Drug: mercaptopurine;   Drug: dasatinib;   Other: laboratory biomarker analysis
Outcome Measures: Overall survival (OS) (Cohort I);   Incidence of dose-limiting toxicity, defined as any grade 3-4 non-hematologic toxicity in the first cycle of post-remission therapy (blinatumomab/dasatinib) (Cohort II);   Complete response (CR + CRi) rate (Cohort I);   Disease-free survival;   Response rates (Cohort II);   OS (Cohort II);   Incidence of toxicity graded according to National Cancer Institute CTCAE version 4.0;   MRD negativity;   Time to achieve MRD negativity
11 Recruiting Early Switch From First-Line Docetaxel/Prednisone to Cabazitaxel/Prednisone and the Opposite Sequence, Exploring Molecular Markers in Men With Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Condition: Prostate Cancer Metastatic
Interventions: Drug: CABAZITAXEL (XRP6258);   Drug: DOCETAXEL (XRP6976);   Drug: Prednisone
Outcome Measures: PSA response rate;   Circulating tumor cells (CTCs) with response to docetaxel or cabazitaxel treatment;   Progression-free survival;   PSA progression-free survival rate;   Objective response rate;   Radiographic progression-free survival (rPFS) rate;   Clinical progression-free survival (cPFS);   Overall survival
12 Recruiting Prednisone Versus Doxycycline in the Treatment of Graves' Orbitopathy
Condition: Thyroid Associated Opthalmopathies
Interventions: Drug: Prednisone+placebo of Doxycycline;   Drug: Doxycycline+placebo of Prednisone
Outcome Measures: Overall treatment response;   • Health related quality of life questionnaires (GO-QoL);   • Safety and tolerability as assessed by adverse events, vital signs;   • Quantitative changes of rectus diameter measured by MRI scan;   Relapse
13 Recruiting A Study of Abiraterone Acetate Plus Low-Dose Prednisone Plus Androgen Deprivation Therapy (ADT) Versus ADT Alone in Newly Diagnosed Participants With High-Risk, Metastatic Hormone-Naive Prostate Cancer (mHNPC)
Condition: Prostate Neoplasms
Interventions: Drug: Abiraterone acetate;   Drug: Prednisone;   Other: Androgen deprivation therapy (ADT);   Drug: Abiraterone acetate Placebo;   Drug: Prednisone Placebo
Outcome Measures: Overall Survival (OS);   Radiographic progression-free survival (PFS);   Time to next skeletal-related event;   Time to prostate specific antigen (PSA) progression;   Time to next subsequent therapy for prostate cancer;   Time to initiation of chemotherapy;   Time to Pain Progression
14 Recruiting Alisertib, Abiraterone Acetate and Prednisone in Treating Patients With Hormone-Resistant Prostate Cancer
Conditions: Adenocarcinoma of the Prostate;   Hormone-resistant Prostate Cancer;   Recurrent Prostate Cancer;   Stage IV Prostate Cancer
Interventions: Drug: Alisertib;   Drug: Abiraterone acetate;   Drug: Prednisone
Outcome Measures: Phase I: Frequency of dose limiting toxicities of Alisertib, graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) v4.1;   Phase II: Duration of progression free survival according to the PCWG2 criteria;   Change in PSA kinetics
15 Recruiting Comparison of Cabazitaxel/Prednisone Alone or in Combination With Custirsen for 2nd Line Chemotherapy in Prostate Cancer
Condition: Prostate Cancer
Interventions: Drug: cabazitaxel, Prednisone, custirsen sodium;   Drug: cabazitaxel, Prednisone
Outcome Measures: Survival;   Progression-free survival at Day 140
16 Recruiting Docetaxel, Prednisone, and Pasireotide in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer
Conditions: Adenocarcinoma of the Prostate;   Hormone-resistant Prostate Cancer;   Recurrent Prostate Cancer;   Stage IV Prostate Cancer
Interventions: Drug: docetaxel;   Drug: pasireotide;   Drug: Prednisone
Outcome Measures: Occurrence of adverse events and the associated grade per NCI Common Terminology Criteria for Adverse Events (CTCAE) version 4.0 to identify the maximum tolerated dose (MTD) of pasireotide in combination with docetaxel and Prednisone;   All specific types of toxicity as assessed via NCI CTCAE version 4.0;   Measurements of tumor using Response Evaluation Criteria In Solid Tumors (RECIST) criteria before and after treatment with the combination of pasireotide in combination with docetaxel;   Percentage prostate-specific antigen (PSA) decline noted;   Time to Progression (TTP);   Overall Survival (OS);   Pharmacokinetics (PK) parameters;   Measurement of levels of IGF-1, serum chromogranin A (SCA), and neuron specific enolase (NSE), pre-therapy, post-therapy, and the change between time points and association with duration of TTP and OS;   Measurements of CTC counts pre-therapy, post-therapy, and the change between time-points and association with duration of TTP and OS
17 Unknown  Therapeutic Effect of Low-dose Prednisone Combined With MMF and FK506 in Focal Segmental Glomerulosclerosis
Condition: Focal Segmental Glomerulosclerosis
Interventions: Drug: Prednisone, FK506, MMF;   Drug: Prednisone
Outcome Measure: proteinuria,serum protein,Scr,blood routine examination,liver function test,blood glucose and lipid test
18 Recruiting Chronic Graft-versus-Host Disease Treatment (BMT CTN 0801)
Condition: Chronic GVHD
Interventions: Drug: Sirolimus + calcineurin inhibitor + Prednisone;   Drug: Sirolimus + Prednisone
Outcome Measures: Phase II: Proportion of subjects with CR/PR;   Phase III: Proportion of subjects with CR; resolution of GVHD manifestations;   Phase II: Avg. daily dose % reduction of Prednisone;   Phase II: Cumulative incidence of treatment failure;   Phase II: Prevalence of active symptomatic chronic GVHD;   Phase II: Incidence of discontinuation of all systemic immunosuppressive therapy;   Phase II: Overall and cancer progression-free survival;   Phase II: Serum biomarkers of chronic GVHD;   Phase III: Avg. daily dose % reduction of Prednisone;   Phase III: Cumulative incidence of treatment failure;   Phase III: Prevalence of active symptomatic chronic GVHD;   Phase III: Incidence of discontinuation of all systemic immunosuppressive therapy;   Phases III: Overall and cancer progression-free survival;   Phase III: Serum biomarkers of chronic GVHD
19 Unknown  Methotrexate as a Steroid-sparing Agent in Idiopathic Retroperitoneal Fibrosis: a Randomised, Multicenter Trial
Conditions: Idiopathic Retroperitoneal Fibrosis;   Perianeurysmal Retroperitoneal Fibrosis;   Chronic Periaortitis
Interventions: Drug: Methotrexate+Prednisone;   Drug: Prednisone
Outcome Measures: Remission rate by the end of treatment;   Reduction in size of the retroperitoneal mass on CT/MRI scans;   Rate of post-treatment relapses;   Treatment-related toxicity
20 Recruiting Finite Androgen Ablation vs. Finite Androgen Ablation in Combination With Abiraterone Acetate and Prednisone
Condition: Prostate Cancer
Interventions: Drug: Lupron;   Drug: Zoladex;   Drug: Degarelix;   Drug: Abiraterone Acetate;   Drug: Prednisone
Outcome Measure: Prostate Specific Antigen (PSA) Free Survival